FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new derivative of uracil described by the following structural formula, and its pharmaceutically acceptable salt. The compound has the structural formula according to the R-enantiomer form: 
The given invention also refers to a method for preparing the above compound and to a pharmaceutical composition on the basis of the above compound. The method for preparing consists in a reaction of 5-fluoruracil and R-tert-butyl-3-iodopropane-1.2-diyldicarbamate.
EFFECT: compound possesses the properties of uridine phosphorylase inhibitors and can be used as an active ingredient for preparing a drug for treating cancer, such as an antimetabolite of the uridine phosphorylase inhibitors of tumour cells.
4 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| REDUCTION METHOD FOR GASTROINTESTINAL TOXICITY CAUSED BY TEGAFUR | 2005 |
|
RU2348409C2 |
| PHOSPHORUS AMIDATE DERIVATIVES OF 5-FLUORO-2'-DEOXYURIDINE APPLICABLE FOR TREATING CANCER | 2012 |
|
RU2614406C2 |
| ADMINISTRATION OF MULTIPLE BOLUSES [6R]-MTHF IN CHEMOTHERAPY BASED ON 5-FLUOROURACIL | 2018 |
|
RU2762596C2 |
| MULTIFUNCTIONAL CONJUGATES OF TACRINE AND ITS ANALOGUES WITH DERIVATIVES OF 1,2,4-TIADIAZOLE, THE WAY OF THEIR SYNTHESIS AND APPLICATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2017 |
|
RU2675794C1 |
| [6R]-MTHF-EFFECTIVE FOLATE ALTERNATIVE IN CHEMOTHERAPY BASED ON 5-FLUOROURACIL | 2018 |
|
RU2763934C2 |
| GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION | 2013 |
|
RU2683260C2 |
| TRIAZOLES USED AS PROTEIN KINASE INHIBITORS | 2005 |
|
RU2393155C2 |
| USE OF 3-O-SULFAMOYLOXY-7Β-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE FOR THE TREATMENT OF BREAST CANCER, INCLUDING A TRIPLE NEGATIVE FORM | 2018 |
|
RU2678845C1 |
| THERAPEUTIC APPLICATION OF YESSOTOXINS AS INHIBITORS OF HUMAN TUMOUR CELL GROWTH | 2004 |
|
RU2389488C2 |
| SYNTHESIS OF RESORCYLIC ACID LACTONES USED AS THERAPEUTIC AGENTS | 2009 |
|
RU2534527C2 |
